Seqker Biosciences

Executive Summary

Seqker Biosciences is a South Korean biotech company focused on developing personalized cancer immunotherapies through its integrated genomic profiling and neoantigen prediction platform. Founded in 2020 and currently in Phase 1 stage, the company leverages its proprietary technology to design and manufacture GMP-grade individualized neoantigen vaccines, as well as provide comprehensive genomic reports for oncology patients. By tailoring treatments to each patient's unique tumor mutational profile, Seqker aims to improve efficacy and reduce off-target effects compared to conventional immunotherapies. The company operates at the intersection of oncology and immunology, positioning itself in the rapidly growing field of precision medicine. Seqker addresses a significant unmet need in cancer care, where many patients fail to respond to standard treatments. The personalized neoantigen vaccine approach has shown promise in early clinical studies globally, and Seqker's platform offers a streamlined, end-to-end solution from genomic analysis to vaccine production. The company is well-positioned to capture value in the expanding personalized cancer vaccine market, which is projected to reach multi-billion dollars by the early 2030s. However, as a private, early-stage firm, Seqker faces typical risks including clinical trial outcomes, manufacturing scalability, and competition from larger players. Success will depend on timely execution of its clinical development plan and securing strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for lead neoantigen vaccine candidate70% success
• Q1 2027Presentation of preclinical efficacy data at a major oncology conference60% success
• Q2 2027Strategic partnership or licensing deal with a global pharmaceutical company30% success